leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye drops in Canada

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye disease.

Janzen telling Proactive this is the first of three products they hope to bring to market and he talks about the size of the market they are looking to try and grab a piece of.

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.11 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $12.29 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Minotaur Exploration's Andrew Woskett highlights its technical credentials...

Minotaur Exploration's (ASX:MEP) Andrew Woskett speaks to Proactive's Andrew Scott soon after announcing they're to proceed with the acquisition of the Pyramid Gold project in north Queensland. The project is 180 kilometres south of Townsville, covers 150 square kilometres and includes two main...

5 hours, 11 minutes ago

2 min read